Cyclacel Pharmaceuticals (NASDAQ:BGMS) Posts Quarterly Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:BGMS) issued its quarterly earnings data on Thursday. The company reported ($0.07) earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.45 million during the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 31.60% and a negative net margin of 118.27%.

Cyclacel Pharmaceuticals Trading Up 6.0%

Cyclacel Pharmaceuticals stock traded up $0.04 during trading on Thursday, reaching $0.71. The company had a trading volume of 18,564 shares, compared to its average volume of 724,049. The firm has a market capitalization of $4.70 million, a price-to-earnings ratio of -0.20 and a beta of -0.44. The firm’s 50-day simple moving average is $0.90 and its 200 day simple moving average is $0.95. Cyclacel Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $2.80.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Tuesday, October 27th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. Its research programs are designed to target key proteins involved in tumor-cell growth, division and survival, with the goal of addressing cancers that have limited treatment options. The company’s pipeline has included fadraciclib (CYC065), an investigational selective cyclin-dependent kinase 2 inhibitor, and sapacitabine (CYC682), an oral nucleoside analog studied in several oncology indications.